Nordic Capital and Permira to acquire Bavarian Nordic for DKK19bn.

Nordic Capital and Permira, a private equity firms, agreed to acquire Bavarian Nordic, a biotechnology company that develops and manufactures vaccines, for DKK19bn. “Our scientific heritage and proven track record of successfully transferring technology and integrating commercial assets has created a unique platform that enables Bavarian Nordic to drive growth and deliver life-saving solutions to patients worldwide. The offer received from Nordic Capital and Permira is the result of intense negotiations aimed at securing the best possible terms for our shareholders. The Board of Directors has unanimously agreed that it intends to recommend that Bavarian Nordic’s shareholders accept the offer when formally submitted. Together with Nordic Capital and Permira, the growth strategy of Bavarian Nordic can be accelerated and strengthen the company’s position in the global vaccine market to the benefit of patients, employees and other stakeholders,” Luc Debruyne, Bavarian Nordi Chair.